Trial Profile
A Phase 1/2 Study of ARRY-520 in Patients With Advanced Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2021
Price :
$35
*
At a glance
- Drugs Filanesib (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 26 Aug 2011 Parimary endpoints added as reported by ClinicalTrials.gov.
- 05 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.